Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd. is a Japanese biopharmaceutical enterprise engaged in the research, development, manufacturing, and marketing of prescription medicines. The company operates as a consolidated research-driven subsidiary of the Roche Group, focusing on oncology, hematology, immunology, and rare disease therapeutic areas. Its primary revenue drivers stem from the sale of proprietary therapeutic antibody drugs, bioengineered pharmaceutical products, global royalty streams, and licensed treatments. Core end markets include hospitals, academic medical centers, specialized healthcare clinics, medical practitioners, and patients across domestic and international markets. The firm invests significantly in proprietary antibody engineering technologies and biopharmaceutical discovery platforms to maintain its pipeline of targeted therapies. Chugai holds a leading market position in the Japanese prescription pharmaceutical sector, particularly within oncology treatments and therapeutic antibodies. Headquartered in Tokyo, Japan, the company's common shares are listed on the Prime Market segment of the Tokyo Stock Exchange under ticker 4519.
65 of the funds FundTelligence covers report a position in Chugai Pharmaceutical.
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 65
Funds holding Chugai Pharmaceutical
- DWS Invest CROCI Japan — DWS · 3.29 % (full portfolio disclosed, June 2026)
- SEB Läkemedelsfond — SEB · 1.44 % (full portfolio disclosed, June 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 1.34 % (full portfolio disclosed, October 2026)
- Danske Invest Japan Index Restricted — Danske Invest · 1.22 % (full portfolio disclosed, July 2026)
- Nordea Japan Portfolio — Nordea Funds · 1.2 % (full portfolio disclosed, September 2026)
- Baillie Gifford Worldwide Responsible Global Alpha Paris-Aligned Fund — Baillie Gifford · 1.09 % (full portfolio disclosed, September 2026)
- T. Rowe Price Global Focused Growth Equity Fund — T. Rowe Price · 0.98 % (full portfolio disclosed, September 2026)
- Baillie Gifford Worldwide Global Alpha Fund — Baillie Gifford · 0.96 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 65 funds holding it.